已收盤 08-07 16:00:00 美东时间
-8.010
-6.76%
华盛资讯8月8日讯,阿克迈公布2026财年Q2业绩,公司Q2营收11.00亿美元,同比增长5.4%,归母净利润0.79亿美元,同比下滑23.4%。
08-08 06:12
Guggenheim analyst John Difucci maintains Akamai Technologies (NASDAQ:AKAM) with a Buy and raises the price target from $181 to $190.
08-08 00:19
Stock index futures were mixed on Friday as investors turned their attention to the closely watched July employment situation report. Dow futures (INDU) -0.06%, S&P 500 futures (SPX) +0.11%, and Nasda...
08-07 16:14
Atlassian暴升31.20%;Twilio暴升17.49%;Cloudflare暴升16.48%
08-07 16:11
华盛资讯8月7日讯,阿克迈公布2026财年Q2业绩,公司Q2营收11.00亿美元,同比增长5.4%,归母净利润0.79亿美元,同比下滑23.4%。
08-07 07:35
Akamai Technologies (NASDAQ:AKAM) narrows FY2026 Adj EPS guidance from $6.40-$7.15 to $6.40-$7.05 vs $6.68 analyst estimate. Narrows FY2026 sales outlook from $4.445 billion-$4.550 billion to $4.445 billion-$4.530 billion vs $4.501 billion estimate.
08-07 04:03
Akamai Technologies (NASDAQ:AKAM) is looking for Q3 Adj EPS of $1.60-$1.80 vs $1.70 analyst estimate. sees sales of $1.105 billion-$1.130 billion vs $1.132 billion analyst estimate.
08-07 04:03
Akamai introduces Workforce Protector, a comprehensive interaction security platform designed for the AI era. It secures workforce interactions in real time, providing visibility, AI governance, and data loss prevention without disrupting user experience or network architecture. The solution integrates seamlessly with Akamai's global network, enabling secure access to applications and data from anywhere. It addresses gaps in traditional security ...
08-05 10:30
Akamai's 2026 report highlights three key AI security risks: the rise of highly active AI power users, unmanaged "shadow AI," and novel attack vectors like Vibe hacking, CursorJacking, and CometJacking. It warns that traditional security tools are inadequate against these threats, as AI now accesses sensitive corporate data directly. The report recommends five strategies for CISOs: targeting high-risk users, eliminating shadow AI, inspecting inte...
08-05 10:30
今日重点评级关注:BTIG:上调Outlook Therapeutics"买入"评级,目标价4美元;TD Cowen:维持Nakamoto"买入"评级,目标价从1美元升至17美元
07-28 11:34